DNA

Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer

NON-REGULATORY PRESS RELEASE The NIPU trial is investigating the effect of adding UV1 vaccine to immunotherapy as second-line treatment of…

3 months ago

Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5

Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality…

3 months ago

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA…

3 months ago

Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer

Britton Russell Britton Russell, Chief Financial Officer, Umoja Biopharma SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja),…

3 months ago

Ocugen Clinical Showcase Webcast Now Available

MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…

3 months ago

GTG to launch U.S. Customer Digital Media Sales Campaign

MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), is pleased to announce the…

3 months ago

Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a…

3 months ago

Recludix Pharma to Participate in Two Investor Conferences in March

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging…

3 months ago

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE)…

3 months ago

HDAI to Present at ViVE 2024 on How Clinicians Can Put AI to Work

BOSTON, Feb. 26, 2024 /PRNewswire/ -- Health Data Analytics Institute (HDAI) – a company pioneering the integration of artificial intelligence into healthcare…

3 months ago